Quick Answer
Kymera Therapeutics, Inc. reported Revenue (ASC 606) of $39.21 million for fiscal year 2025.
Kymera Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $39.21M | -16.7% |
| 2024 | $47.07M | -40.1% |
| 2023 | $78.59M | +67.8% |
| 2022 | $46.83M | -35.7% |
| 2021 | $72.83M | +114.0% |
| 2020 | $34.03M | +1060.0% |
| 2019 | $2.93M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.76M | -26.1% | -75.9% |
| June 30, 2025 | $11.48M | -55.3% | -48.1% |
| March 31, 2025 | $22.10M | +114.8% | +490.8% |
| September 30, 2024 | $3.74M | -20.9% | -85.4% |
| June 30, 2024 | $25.65M | +55.3% | +149.3% |
| March 31, 2024 | $10.29M | +8.7% | +117.6% |
| September 30, 2023 | $4.73M | -50.5% | -71.4% |
| June 30, 2023 | $16.51M | +43.4% | +74.4% |
- Kymera Therapeutics, Inc. showed a decrease of -16.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2019–2025 period, Kymera Therapeutics, Inc.’s revenue (asc 606) has grown by 1236.4% (from $2.93 million to $39.21 million).
- The most recent figure is from Kymera Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: